TRANSIL XL Assay Kit for Microsomal Binding


TRANSIL XL Assay Kit for Microsomal Binding


Sovicell Logo 100x94

Products & Services | Sovicell GmbH

Sovicell’s TRANSILXL Microsomal Binding Kit provides a fast high throughput assay based on the affinity to human liver microsomal membranes.

The Microsomal Binding Kit is one of Sovicell’s range of ready-to-use assay systems for DMPK and ADMET studies.

The kit is based on a ready-to-use 96-well microtiter plate carrying TRANSIL beads with a single lipid bilayer reconstituted from with a single lipid bilayer reconstituted from synthetic lipids resembling a natural composition of human liver micromes. It can be used to estimate the affinity to human microsomal membranes and determine microsomal binding, with rapid compound quantification due to immobilized brain membranes.

Design and features

The TRANSILXL Microsomal Binding assay kit is designed for automated liquid handlers or manual pipetting. It consists of ready-to-use 96-well microtiter plates. One plate can be used for measuring microsomal binding of up to 12 compounds.

The assay requires just five steps:

  1. Addition of drug candidate
  2. Mixing and incubation for 12 minutes
  3. Removal of beads by centrifugation
  4. Sampling of supernatant
  5. Quantification of drug candidate

The included spreadsheet enables easy calculation of final results, with a ‘traffic light’ system for data quality rating.

Background and Technical Information

In initial drug research, the main emphasis is on being able to predict the pharmacokinetics of the drug in humans to help identify candidates with appropriate characteristics, with metabolic clearance as a key parameter to be quantified.

This can be achieved either via extrapolation using allometry or through translating an understanding of metabolic stability in preclinical non-human species, liver microsomes and hepatocytes to those in human. In the latter case, there has often been the assumption that the concentration added to the microsome or hepatocyte incubation is the same as the unbound concentration in the incubation.

Recent research has shown that binding to microsomes and hepatocytes can be significant, and hence the unbound concentration is lower than the total concentration added, often resulting in a dramatic effect on the estimate of clearance. Consequently, it is important to estimate microsomal binding in these in vitro incubations.

Binding to microsomal membranes is often estimated as the free fraction of drug in incubations of microsomes (without cofactor) in dialysis rigs, requiring overnight incubations. These experiments can often suffer from compound instability through hydrolysis and precipitation of poorly soluble drugs. Moreover, the free fraction which is determined experimentally relates to the experimental concentration of microsomes which will in many cases differ from the incubations that have occurred with the metabolic stability experiments.

To adjust the free fractions in the microsomal binding experiment to the free fractions in the metabolic stability experiment an equation developed by Austin and coworkers is used. However, this equation is limited in the range concentration changes of microsomal incubations.

Use of the TRANSILXL Microsomal Binding Assay can overcome all these limitations.

Applications

Microsomal binding not only reduces the concentration of free drug available to be metabolized by CYP enzymes, it also reduces the concentration available to inhibit the enzymes. Since non-specific microsomal binding can account for underestimation of inhibitor potency (i.e., overestimation of IC50 or Ki values) when dealing with lipophilic basic drugs, this in turn can lead to an underestimation of risk of drug-drug interactions.

In particular, mechanism based inhibitor studies can be affected to a large extent by microsomal binding, because of the high microsome concentrations that are typically employed in these experiments. Hence, the fraction of drug bound to microsomes is also an important correction of experiments assessing the inhibition potential.

The TRANSILXL Microsomal Binding Kit is compatible with a range of detection systems, including LC/MS/MS and Scintillation counting.

Parameters can be estimated and predicted for affinity to human liver microsomes, Human fu(mic), with applications for fu(mic) in other species being developed.

Benefits

  • TRANSIL beads are integrated into 96-well microtiter plates to enable easy handling
  • One plate can be used for measuring microsomal binding of up to 12 compounds
  • Only 12 minutes assay incubation time
  • Rapid compound quantification due to immobilized plasma proteins (e.g. injection via RapidFire™)
  • Highly reproducible results and robust correlation with conventional dialysis technique

Resources

Click on TRANSIL Microsomal Binding Kit for more information.
Click on Sovicell to contact the company directly.
Click on Technical Information to download PDF fact sheet.

The TRANSIL Microsomal Binding Kit is based on 96-well microtiter plate for easy handling and convenience

The TRANSIL Microsomal Binding Kit is based on 96-well microtiter plate for easy handling and convenience

Each TRANSIL Microsomal Binding bead includes a single lipid bilayer reconstituted from synthetic lipids resembling a natural composition of human liver micromes

Each TRANSIL Microsomal Binding bead includes a single lipid bilayer reconstituted from synthetic lipids resembling a natural composition of human liver micromes

Influence of microsomal binding on clearance rate estimation, comparing two compounds with identical clearance rate. Dark blue line represents a compound that does not bind to microsomes, while the light blue line represents a compound that binds strongly at fu(mic)=10%. The intrinsic clearance rate of the compound binding to microsomes is highly underestimated.

Influence of microsomal binding on clearance rate estimation, comparing two compounds with identical clearance rate. Dark blue line represents a compound that does not bind to microsomes, while the light blue line represents a compound that binds strongly at fu(mic)=10%. The intrinsic clearance rate of the compound binding to microsomes is highly underestimated

Comparison of microsomal binding measurements between the TRANSIL Microsomal Binding Kit and conventional dialysis. The test set comprised alprenolol, amantadin, buspirone, carbamazepine, cyclobenzaprine, desipramine, diphenhydramine, Enalaprilat, fexofenadine, fluoxetine, fluvoxamine, faloperidol, ketoconazol, labetalol, levofloxazine, nalidixic acid, nortriptyline, promazine, propranolol, sulfasalazine, terazosin, venlafaxine, and warfarin..

Comparison of microsomal binding measurements between the TRANSIL Microsomal Binding Kit and conventional dialysis. The test set comprised alprenolol, amantadin, buspirone, carbamazepine, cyclobenzaprine, desipramine, diphenhydramine, Enalaprilat, fexofenadine, fluoxetine, fluvoxamine, faloperidol, ketoconazol, labetalol, levofloxazine, nalidixic acid, nortriptyline, promazine, propranolol, sulfasalazine, terazosin, venlafaxine, and warfarin

Supplier Information
Supplier: Sovicell GmbH
Address: Deutscher Platz 5a, 04103 Leipzig, Germany
Tel: +49 341 520440
Website: http://www.sovicell.com


Comments are closed.